Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions Inc. (NYSE: EBS) regularly issues news and updates that reflect its focus on public health threats and pharmaceutical preparation manufacturing. Company announcements highlight developments across its commercial naloxone franchise, medical countermeasures portfolio, manufacturing network and financial performance, providing context for how Emergent pursues its stated mission to protect and save lives.
News items frequently cover product and regulatory milestones, such as U.S. Food and Drug Administration approvals and supplemental applications. Examples include FDA approval of over‑the‑counter NARCAN® Naloxone HCl Nasal Spray 4 mg and approval of a supplemental Biologics License Application for raxibacumab manufacturing at Emergent’s Winnipeg, Canada facility. Releases also describe new packaging options, such as the NARCAN® Nasal Spray carrying case designed to make naloxone easier to carry and more discreet.
Emergent’s news flow also features government contracts and contract modifications for medical countermeasures. Recent announcements describe delivery orders and options to supply BioThrax® (Anthrax Vaccine Adsorbed), ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), TEMBEXA® and BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to U.S. government agencies responsible for preparedness and response.
Investors and observers can also find financial and corporate updates, including quarterly earnings releases, segment performance commentary, debt prepayments under term loan facilities, and notices of presentations at healthcare conferences. Additional news addresses board‑level changes and corporate governance matters.
Other communications focus on public health initiatives and collaborations, such as support for opioid poisoning awareness observances, partnerships aimed at increasing workplace access to naloxone, and collaboration with PANTHER and Africa CDC on the MpOx Study in Africa. Together, these updates offer insight into how Emergent’s products, contracts, research collaborations and financial decisions relate to its role in addressing health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies.
Emergent BioSolutions (NYSE: EBS) reported Q1 2026 revenue of $156.1 million, net income of $6.8 million (4% margin) and adjusted EBITDA of $35.6 million (23% margin).
The company completed a $150 million term loan refinancing, secured strategic manufacturing partnerships including Substipharm, authorized up to $50 million of share repurchases, and won material government contracts including ~$140 million with Canada.
Emergent BioSolutions (NYSE:EBS) said Singapore’s Health Sciences Authority approved an expanded indication for ACAM2000 to include prevention of mpox in adults at high risk for mpox infection.
The approval is supported by existing human safety data and a controlled animal study showing vaccine effectiveness, and permits use during severe mpox outbreaks when alternatives are unavailable or contraindicated.
Emergent BioSolutions (NYSE: EBS) signed a multi-year manufacturing agreement with SAB Biotherapeutics to support development and manufacturing of SAB-142, a type 1 diabetes clinical candidate. The contract value is approximately $50 million, with $36 million contingent on regulatory approval and downstream milestones. Emergent will provide end-to-end process development, scale-up, analytical transfer, clinical manufacturing and potential commercial manufacture at its Winnipeg, Manitoba facility, which will act as the primary site for bulk intermediate and drug product production for SAB-142.
Emergent BioSolutions (NYSE: EBS) partnered with professional baseball player Davis Schneider to raise awareness of NARCAN® Nasal Spray in Canada and to reduce stigma around opioid poisonings. Schneider shares his family story on Emergent’s Opioid Crisis Impact Map to encourage preparedness and naloxone access.
The release notes an average of 17 lives lost daily to opioid poisoning in Canada and > 53,000 lives lost since 2016. Since 2018, Emergent has delivered more than 100 million doses of NARCAN® Nasal Spray across Canada and the U.S., and lists provincial, territorial and other program access points and an online ordering option.
Emergent BioSolutions (NYSE: EBS) and Substipharm Biologics agreed to a ≈$34.5 million manufacturing services and distribution collaboration dated April 28, 2026. Emergent’s Canton, MA facility will manufacture IMOJEV® drug substance and serve as exclusive U.S. government distributor upon FDA approval.
The Canton site received an FDA "No Action Indicated" classification after a February 2026 inspection; Emergent has begun scale-up work and expects to hire additional staff later in 2026.
Emergent BioSolutions (NYSE: EBS) will report first quarter 2026 financial results and host a conference call on April 30, 2026 at 5:00 p.m. ET.
Investors can join via live webcast on the company Investors page or register for telephone access; a replay will be posted on the Investors page.
Emergent BioSolutions (NYSE: EBS) closed a new $150 million term loan with OrbiMed and amended its asset-backed revolving loan to $50 million, extending maturities for both facilities to April 16, 2031. Interest on the new term loan was reduced by 200 basis points, and covenant flexibility and incremental debt capacity were expanded to support the company’s multi-year transformation plan.
The proceeds repaid the prior term loan, and the ABL amendment increases operational flexibility and borrowing options to pursue strategic initiatives.
Emergent BioSolutions (NYSE: EBS) announced a supply partnership with the B.C. Provincial Health Services Authority to provide NARCAN® Nasal Spray as British Columbia expands its Take-Home Naloxone Program following an $18 million CAD provincial investment.
The rollout expands a 2024 pilot that delivered 60,000 nasal kits; Emergent reports delivering >100 million NARCAN doses in Canada and the U.S. since 2016 and employs over 300 people in Canada.
Emergent BioSolutions (NYSE: EBS) on April 7, 2026 launched a new NARCAN® Nasal Spray Carrying Case, expanded 6-count and 24-count multipacks, and began a college outreach effort titled Ready to Rescue featuring Emmitt Smith and Zac Clark.
The initiatives aim to increase naloxone access, address low carry rates, and support campus preparedness; carrying case is available on Amazon and multipacks on NarcanDirect.com.
Emergent BioSolutions (NYSE: EBS) said members of its products, medical affairs, government and public affairs teams will participate in four international preparedness conferences in April–June 2026.
Conferences listed include London Defence Conference (April 10–11), CBRN Research & Innovation (May 19–21), Global Health Security (June 9–12) and BIO International Convention (June 20–22). The company emphasized collaboration with governments on medical countermeasures for threats such as smallpox, anthrax, botulism and Ebola.